Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
25 hedge funds and large institutions have $12.2M invested in Cellular Biomedicine Group, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
138% more capital invested
Capital invested by funds: $5.13M → $12.2M (+$7.05M)
47% more funds holding
Funds holding: 17 → 25 (+8)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $209K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 2 |
Goldman Sachs
New York
|
+$967K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$788K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$508K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$316K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$114K |
| 2 |
BlackRock
New York
|
-$31.4K |
| 3 |
Barclays
London,
United Kingdom
|
-$11K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$9.08K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$7.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| – | -$5K | -453 | Closed |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1.68K | -92 | -75% |
|
CBMG Hedge Fund Activity: Q1 2018 in Review
25 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2018, worth a combined $12.2M — up 138% from $5.13M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBMG positions and 2 closed out — a net gain of 8 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.08M. The largest seller was Zurich Cantonal Bank, exiting entirely with an estimated $114K sold.
- 25 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2018, up from 17 in Q4 2017.
- Funds reported $12.2M of Cellular Biomedicine Group, Inc. stock for Q1 2018, up 138% quarter-over-quarter.
- 10 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2018 and 2 closed out, a net change of +8 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q1 2018 was Vanguard Group, an estimated $1.08M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2018 was Zurich Cantonal Bank, an estimated $114K sold.
Based on aggregated 13F filings for Q1 2018.